A group of Canadian patient organizations, mainly but not solely comprised of cancer groups, responded to the pre-consultation call for input from the Patented Medicine Prices Review Board (PMPRB) on proposed amendments to the Regulations to the Patent Act. The response submitted by the patient organizations called on the federal government to ensure that there would be no unintended or unforeseen adverse consequences to Accessibility or Appropriate Use, the other two pillars of the federal health goals along with Affordability (the 3As), as a result of the proposed changes. In addition, many suggestions we made to address the issue of drug affordability underpinning the objectives of proposed changes.
The patients organizations believe that the patient voice must be heard on these proposed changes and are of the strong belief that, if enacted as proposed, the amendements may well result in:
- less access to necessary medicines for Canadians, either because fewer drugs will be launched or because, according to research published in a number of papers on similar pricing regulations enacted in other jurisdictions, there will be significantly longer delays in the launch of new drugs in Canada than presently.
- fewer clinical trials being made available to Canadian patients due to the adverse impact of the proposed changes on research incentives and investments.